Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.

The company reported third-quarter sales of $11.37 billion, slightly missing the consensus of $11.40 billion. The U.S. MedTech giant reported adjusted earnings of $1.30, in line with Wall Street estimates and within the management guidance of $1.28-$1.32.

“Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance,” said Robert B. Ford, chairman and chief executive officer, Abbott. “Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders.”

Abbott Laboratories narrowed its fiscal 2025 adjusted earnings guidance from $5.10 to $5.20 per share to ...